Skip to content

Effects of different doses of esketamine combined with propofol in painless abortion

Effects of different doses of esketamine combined with propofol in painless abortion

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058324
Enrollment
Unknown
Registered
2022-04-06
Start date
2022-03-29
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abortion

Interventions

Group A:Low-dose esketamine
Group B:Medium-dose esketamine
Group C:High-dose esketamine

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-45 years, BMI 18-28 kg/m^2, ASA I or ?; 2. Clearly understand and voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous vaginal delivery; 2. Hearing impairment, unable to cooperate with respondents to complete the questionnaire; 3. Patients with significant respiratory dysfunction before surgery (obstructive sleep apnea syndrome, acute respiratory tract infection, acute onset of chronic obstructive pulmonary disease, uncontrolled asthma, etc.); 4. Patients with circulation dysfunction before surgery (Unstable angina pectoris; Myocardial infarction occurred within 6 months before screening; Resting ECG heart rate =450ms, female >=470ms); 5. Anemia or thrombocytopenia: Hb < 90g/L, PLT < 80x10^9/L; 6. Patients with mental diseases (schizophrenia, mania, bipolar disorder, mental disorder, etc.), long-term use of psychotropic drugs and cognitive dysfunction; 7. Patients suffering from infectious diseases (hepatitis B, tuberculosis, HIV, syphilis, etc.); 8. Patients who take opioids every day for 1 month or intermittently for nearly 3 months, and are allergic or contraindicated to research drugs, opioids, propofol and other drugs and their components; 9. Patients judged to have difficulties in respiratory tract management: modified Martenberg score ? or above; 10. Patients participating in other clinical trials; 11. The investigator considered the patients unfit to participate in this study.

Design outcomes

Primary

MeasureTime frame
Low blood pressure;

Secondary

MeasureTime frame
Perioperative hemodynamics;Time indicator;

Countries

China

Contacts

Public ContactChen Jiejuan

Affiliated Hospital of Guizhou Medical University

2274860532@qq.com+86 13639136003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026